Rituximab as first-line treatment of pemphigus.
Department of Dermatology, University of Lübeck, Lübeck, D-23538, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. Electronic address: enno.schmidt@uksh.de.
Enno
E
Schmidt
D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D010392:Pemphigus / Q000188:drug therapy*; D012008:Recurrence; D000069283:Rituximab / Q000627:therapeutic use*; D016896:Treatment Outcome
D000074322:Antineoplastic Agents, Immunological; D000069283:Rituximab